TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers, has announced significant advancements in its global intellectual property portfolio. The company revealed that IP Australia has accepted Patent Application No. 2019349817, which covers therapeutic nanoparticle compositions designed to deliver small interfering RNA (siRNA) molecules for cancer treatment. The allowed claims encompass nanoparticle compositions and methods of use across a range of cancers, including colon, lung, breast, pancreatic, and ovarian cancers. This application is expected to proceed to grant with a projected expiration date of September 6, 2039, providing long-term protection for the company's innovative approach to RNA-based cancer therapies.
In addition to the Australian milestone, TransCode Therapeutics received a Notice of Allowance from the Japan Patent Office (JPO), followed by the grant and issuance of Japanese Patent No. 7886877. This patent covers RNA-based immunomodulatory compositions designed to selectively activate innate immune pathways within tumors and the tumor microenvironment. The Japanese claims include compositions targeting cancers expressing miR-21 and nanoparticle-enabled delivery approaches incorporating magnetic or polymer-coated systems. These patents are crucial for TransCode as they bolster the company's ability to protect its proprietary technologies in key global markets.
The implications of these patent allowances are substantial for TransCode Therapeutics and the broader oncology field. With a robust intellectual property portfolio, the company is better positioned to attract investment and partnerships, accelerating the development of its therapeutic candidates. The lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. By securing patents in Australia and Japan, TransCode not only safeguards its innovations but also enhances its competitive edge in the race to bring novel RNA-based cancer treatments to market. This is particularly important as the demand for effective cancer therapies continues to rise globally.
For investors and industry observers, these developments signal TransCode's commitment to building a strong foundation for its pipeline. The company's focus on immuno-oncology and RNA therapeutics aligns with the growing trend of precision medicine, which aims to tailor treatments to the specific genetic and molecular profiles of cancers. As TransCode advances its clinical programs, the protection afforded by these patents could translate into significant commercial value. The news was distributed through InvestorWire, a specialized communications platform for wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio @ IBN, which offers access to a vast network of wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit TransCode Therapeutics (NASDAQ: RNAZ).
The full press release can be viewed at https://ibn.fm/Pqy4e, and the latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ. InvestorWire (IW) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. For more information, please visit https://www.InvestorWire.com. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
